Valbiotis Shares Surge 11% Following European Vote on Red Yeast Rice
Valbiotis shares are soaring in mid-session trading, continuing the momentum triggered by the European vote on monacolins from red yeast rice. The session is marked by a significant technical breakthrough in a Parisian market that is otherwise trending downward.
European Vote on Monacolins Reignites Interest in Valbiotis' Positioning
Valbiotis shares jumped 11.21% to €1.19 at midday, while the CAC 40 is down 0.29% and the SBF 120 is down 0.23%. The movement comes the day after the EU member states voted in favor of a draft regulation aiming to ban monacolins derived from red yeast rice in dietary supplements. The company highlights its product ValbiotisPRO Cholesterol, formulated without monacoline K or red yeast rice, which directly aligns its offering with the European regulatory trajectory on cardiometabolic prevention. Today's rise brings the weekly performance to 13.33% and the gain over three months to nearly 16%.
Breakthrough of Resistance at €1.21 Followed by a Dip Below the Threshold
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The stock broke through its resistance at €1.21 during the session, reaching a high of €1.25, before falling back below this level (last price at €1.19). This foray beyond the major technical area reflects the buying strength triggered by the potential regulatory evolution, although the breakout has not yet been consolidated. The price is significantly above its three moving averages, with a 15.5% gap from the MM20 (€1.03) and over 41% from the MM200 (€0.84), indicating a strong underlying bullish trend. The RSI at 53 remains in the neutral zone, leaving room before a potential overbought signal. The ability of the price to reestablish above €1.21 is the technical element to watch in the coming sessions.
Related
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 0,8 millions d'euros
Quarterly revenue: 0,8 millions d'euros
Net income: -3,4 millions d'euros
Guidance from the release
« Valbiotis renonce par prudence à son ambition de chiffre d'affaires à 3 M€ sur l'ensemble de l'exercice 2026 » et retire ses ambitions 2027 et 2030
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.